ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the SHARE™️ Series Monday Management Update for investors on Monday, September 18, 2023, at 11:00 am ET.

2023年9月12日亚特兰大（GLOBE NEWSWIRE）-Virios Therapeutics，Inc。（纳斯达克股票代码：VIRI）（“公司”），一家发展阶段的生物技术公司，专注于推进新型抗病毒疗法，以治疗衰弱的慢性疾病，如纤维肌痛（“FM”）和长新型冠状病毒肺炎（“LC”），今天宣布主席兼首席执行官格雷格·邓肯将出席该股份™️ 投资者系列周一管理更新于2023年9月18日星期一上午11点开始。

This virtual event combines a brief corporate overview with a moderated fireside chat and provides access to individual and institutional investors who will have the opportunity to submit questions during the live session. A link to the live and archived webcast may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations.

此虚拟事件将简短的公司概述与有节制的火柴聊天相结合，并提供对个人和机构投资者的访问权限，这些投资者将有机会在实时会话期间提交问题。可以在Virios Therapeutics网站的“投资者”部分“事件和演示”下访问到实时和存档的网络广播的链接。

About Virios Therapeutics Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as such as fibromyalgia (“FM”) and Long-COVID (“LC”). Overactive immune response related to activation of tissue resident herpesvirus has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel syndrome, LC, chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease, often triggered by events which compromise the immune system.

关于Virios Therapeutics Virios Therapeutics（纳斯达克股票代码：VIRI）是一家发展阶段的生物技术公司，致力于推进新型抗病毒疗法，以治疗与病毒引发的异常免疫反应相关的疾病，如纤维肌痛（“FM”）和长新型冠状病毒（“LC”）。已经假定与组织驻留疱疹病毒活化有关的过度活跃的免疫应答是慢性疾病的潜在根本原因，例如FM，肠易激综合征，LC，慢性疲劳综合征和功能性躯体综合征，所有这些疾病的特征在于打蜡和减少的疾病表现，通常由损害免疫系统的事件引发。

Our lead development candidates are novel, proprietary, fixed dose combinations of an antiviral compound and celecoxib designed to synergistically suppress herpesvirus replication, with the end goal of reducing virally promoted disease symptoms. IMC-1 (fixed dose combinati.

我们的主要开发候选药物是抗病毒化合物和塞来昔布的新型专有固定剂量组合，旨在协同抑制疱疹病毒复制，最终目标是减少病毒促进的疾病症状。IMC-1（固定剂量组合）。